Zimmer Biomet (NYSE:ZBH) Given Hold Rating at Needham & Company LLC

by · The Cerbat Gem

Zimmer Biomet (NYSE:ZBH – Get Free Report)‘s stock had its “hold” rating reissued by research analysts at Needham & Company LLC in a research note issued on Thursday, Benzinga reports.

A number of other brokerages also recently commented on ZBH. BTIG Research dropped their price objective on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a research report on Thursday, October 3rd. Royal Bank of Canada dropped their price objective on shares of Zimmer Biomet from $130.00 to $120.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. UBS Group dropped their price objective on shares of Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating on the stock in a research report on Thursday, August 8th. Oppenheimer dropped their price objective on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 15th. Finally, Robert W. Baird dropped their price objective on shares of Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Zimmer Biomet currently has an average rating of “Hold” and an average price target of $123.94.

View Our Latest Stock Report on Zimmer Biomet

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $109.77 on Thursday. The firm has a market cap of $22.58 billion, a PE ratio of 23.76, a price-to-earnings-growth ratio of 1.88 and a beta of 1.02. Zimmer Biomet has a 52-week low of $101.47 and a 52-week high of $133.90. The company has a quick ratio of 0.63, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. The company’s 50 day moving average is $107.24 and its two-hundred day moving average is $111.03.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last released its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.75 by ($0.01). The business had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a return on equity of 12.86% and a net margin of 13.25%. Zimmer Biomet’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter last year, the company earned $1.65 earnings per share. On average, research analysts expect that Zimmer Biomet will post 7.97 EPS for the current fiscal year.

Institutional Investors Weigh In On Zimmer Biomet

A number of institutional investors have recently added to or reduced their stakes in the business. BLB&B Advisors LLC lifted its position in shares of Zimmer Biomet by 2.1% during the 3rd quarter. BLB&B Advisors LLC now owns 4,900 shares of the medical equipment provider’s stock valued at $529,000 after acquiring an additional 100 shares during the period. Financial Advocates Investment Management raised its holdings in Zimmer Biomet by 3.5% in the 3rd quarter. Financial Advocates Investment Management now owns 3,053 shares of the medical equipment provider’s stock valued at $330,000 after acquiring an additional 103 shares during the last quarter. PFG Advisors raised its holdings in Zimmer Biomet by 5.5% in the 1st quarter. PFG Advisors now owns 2,004 shares of the medical equipment provider’s stock valued at $265,000 after acquiring an additional 105 shares during the last quarter. M&R Capital Management Inc. raised its holdings in Zimmer Biomet by 14.1% in the 3rd quarter. M&R Capital Management Inc. now owns 852 shares of the medical equipment provider’s stock valued at $92,000 after acquiring an additional 105 shares during the last quarter. Finally, Mill Creek Capital Advisors LLC raised its holdings in Zimmer Biomet by 5.1% in the 2nd quarter. Mill Creek Capital Advisors LLC now owns 2,195 shares of the medical equipment provider’s stock valued at $238,000 after acquiring an additional 106 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

(Get Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

See Also